RASĀYAN *J. Chem.*
Vol. 18 | No. 4 | 2301-2308 | October-December | 2025
ISSN: 0974-1496 | e-ISSN: 0976-0083 | CODEN: RJCABP
http://www.rasayanjournal.com
http://www.rasayanjournal.co.in

NANOTECHNOLOGY IN PHARMA: REVOLUTIONIZING DRUG DELIVERY AND SHAPING THE FUTURE OF PHARMACEUTICAL MARKETING

M. Narayan✉, A. K. Srivastava and S. Basak
Amity University Jharkhand, Ranchi, **835303**, India
✉Corresponding author: msnarayan07@gmail.com

ABSTRACT

Nanotechnology enables revolutionary drug delivery through enhanced precision, bioavailability, and personalized therapies, but faces critical clinical and commercial barriers. This study analyzes how nanoparticle physicochemical properties, including size, shape, and surface charge, overcome biological barriers such as the blood-brain barrier, evaluating innovations in stimuli-responsive systems like thrombin-activated nanoparticles for ischemic tissue targeting and magnetic field-guided carriers alongside biodegradable polymer-based platforms. Commercialization challenges were assessed using clinical evidence and market data, revealing nanoparticles' efficacy in targeted delivery for stroke, cancer, and neurological disorders while identifying manufacturing scalability limitations, batch-to-batch inconsistencies, regulatory fragmentation, and high production costs as key impediments to clinical adoption. Approved nanotherapies validate therapeutic advantages yet underscore persistent translation hurdles. To unlock nanotechnology's projected $627 billion market value by 2034, stakeholders must implement AI-driven manufacturing to ensure reproducibility, adopt sustainable production methods to mitigate toxicity, and harmonize global regulatory frameworks, as integrating technical innovation with pragmatic commercialization strategies remains essential for next-generation therapeutics that contribute to equitable health outcomes (SDG-3).

Keywords: Nanotechnology, Drug Delivery, Nanoparticles, Personalized Medicine, Stimuli-Responsive Systems, Nanomedicine, Biodegradable Polymers, SDG-3.

RASĀYAN *J. Chem.*, Vol. 18, No. 4, 2025

INTRODUCTION

Nanotechnology has emerged as a transformative force in pharmaceutical sciences, redefining drug delivery through precision-engineered nanoparticles (NPs) that overcome the limitations of conventional therapeutics.[1,2] These nanocarriers, typically ranging from 1 to 100 nm, address two fundamental challenges in drug development: poor bioavailability and nonspecific biodistribution.[3] By encapsulating active compounds from small molecules to nucleic acids, NPs protect payloads from degradation while enabling controlled release at target sites.[4] Their adaptability is exemplified by thrombin-responsive NPs that dynamically shrink in ischemic tissues to penetrate the blood–brain barrier (BBB), a critical advance for stroke therapy where thrombin overexpression acts as a biological trigger.[5] This protease-activated size modulation, combined with receptor targeting (e.g., CXCR4-binding AMD3100 ligands), has demonstrated enhanced delivery of neuroprotective agents like glyburide in preclinical models, reducing cerebral edema while minimizing systemic toxicity.[6] The success of nanocarriers hinges on their physicochemical properties.[7] Size dictates biodistribution: particles below ~5 nm undergo renal clearance, while those exceeding ~150 nm are sequestered by the reticuloendothelial system.[8] Intermediate-sized NPs (10–50 nm) exhibit optimal tissue penetration, especially in tumors and ischemic regions.[8] Shape also influences efficacy; rod-shaped NPs outperform spherical ones in BBB transcytosis.[9] ,[10] Surface charge plays a pivotal role: neutral or anionic NPs like PEGylated liposomes evade immune detection, whereas cationic NPs often bind nonspecifically.[11] These design principles are critical, considering ~40% of drug candidates fail due to poor solubility, a hurdle mitigated by nanocrystals and polymeric micelles that enhance dissolution of hydrophobic compounds.[12] For biologics like mRNA, nanocarriers are indispensable, improving delivery efficiency from less than 0.01% (free

http://doi.org/10.31788/RJC.2025.1849428

mRNA) to clinically viable levels, as demonstrated by lipid nanoparticles (LNPs) in COVID-19 vaccines.[5] ,[13]

Stimuli-responsive systems represent another frontier.[14] Beyond thrombin-triggered platforms, magnetic iron oxide NPs (Fe_3O_4) enable tumor-specific drug accumulation via external magnetic guidance, though their limited penetration depth and iron-related toxicity remain challenges.[15] Biodegradable polymers like PLGA offer sustained release while degrading into non-toxic metabolites[16] , though long-term accumulation requires scrutiny.[17] Clinically approved nanotherapies include liposomal doxorubicin (Doxil®), which reduces cardiotoxicity[18,19] and albumin-bound paclitaxel (Abraxane®), which enhances solubility and tumor targeting.[20] These successes underscore nanotechnology's potential in treating cancer, neurological disorders, and infectious diseases[21]. However, translation from bench to bedside faces significant barriers.[22] Figure-1 illustrates the role of stimuli-responsive nanocarriers in overcoming these challenges. Manufacturing complexities, phase variability, and high costs persist even for established nanomedicines like Doxil®, which is about three times more expensive than conventional doxorubicin.[18] Figure-2 highlights the various nanoparticle-based drug delivery systems that contribute to these obstacles. Regulatory frameworks remain fragmented, with divergent FDA and EMA requirements delaying approvals.[23] Commercial viability is further hampered by the need to demonstrate cost benefit superiority highlighted by Onpattro® (a ~$450,000/year siRNA therapy) despite proven efficacy.[1] Safety concerns linger, particularly around inorganic NPs (e.g., gold, iron oxide), where long-term biocompatibility data remain limited[24] . The future of nanomedicine lies in interdisciplinary innovation, including AI-driven NP design for scalable manufacturing[25] , green nanotechnology for sustainable synthesis[26] , and personalized approaches like folate receptor-targeted dendrimers.[27] Pharmaceutical marketing strategies must also evolve to effectively communicate the value proposition of nanomedicines to healthcare providers.[51] Despite projections that the nanomedicine market will reach $627 billion by 2034[28], challenges persist in optimizing nanoparticle properties, ensuring scalability, standardizing manufacturing, and navigating regulatory and commercial hurdles. This paper investigates these challenges through the lens of nanoparticle design, clinical translation, and market integration. It explores how biodegradable polymers (e.g., PLGA) and stimuli-responsive systems improve delivery efficiency and mitigate toxicity, and evaluates targeted nanocarriers like folate receptor–directed dendrimers for personalized medicine. Synthesizing advancements in AI-driven optimization, green nanotech, and biomarker-based targeting, this work seeks to bridge the gap between innovation and clinical implementation, emphasizing interdisciplinary collaboration to align scientific breakthroughs with ethical, economic, and regulatory priorities, positioning nanotechnology as a cornerstone of next-generation healthcare.



Fig.-1: Mechanisms of Endogenous and Exogenous Stimuli-Responsive Nanocarriers for Targeted Drug Delivery



Fig.-2: Classification of Nanoparticle-Based Drug Delivery Systems by Carrier Type and Structure

Nanotechnology is fundamentally reshaping personalized medicine through AI-integrated platforms and engineered tissue models. Nano-embedded 3D tumour systems[17] provide precise chemotherapy screening platforms, while machine learning algorithms analyze patient data to predict individual responses to nanomedicines.[25] This synergy enables biomarker-driven therapies like folate receptor-targeted dendrimers that exploit cancer-specific overexpression.[27] Concurrently, nanotechnology

revolutionizes diagnostics: quantum dots enable real-time tumour tracking with unprecedented resolution[29], while nanoparticle biosensors detect pathogens like SARS-CoV-2 at ultralow viral loads.[30] The emerging theranostics paradigm merges diagnosis and treatment, exemplified by iron oxide nanoparticles serving dual roles as MRI contrast agents and targeted chemotherapy carriers.[31] Recent advances in drug delivery focus on stimuli-responsive nanoplatforms. Temperature-sensitive liposomes enable spatial control of drug release[32], while pH/redox-activated polymeric nanoparticles exploit tumour microenvironments for triggered payload deployment[14]. For nucleic acid delivery, lipid nanoparticles (critical to COVID-19 vaccines[33]) and cell-penetrating peptides[34] overcome mRNA stability challenges. Novel targeting strategies include engineered exosomes harnessing natural homing mechanisms[35] and biomarker-directed systems like folate-conjugated dendrimers.[27] Clinical validation continues to grow with nanotherapeutics demonstrating significant advantages. Liposomal irinotecan (Onivyde®) improves survival in pancreatic cancer[36], while Vyxeos® (daunorubicin/cytarabine liposomes) enhances outcomes in acute myeloid leukemia.[37] The nanomedicine market reflects this progress - valued at $209 billion in 2024 and projected to reach $627 billion by 2034[28], driven by demand for targeted therapies despite persistent commercialization barriers like high production costs and regulatory fragmentation.[22] Safety considerations remain paramount in nanomaterial design. Biodegradable systems like polylactic acid nanoparticles[19] and clearance-optimized architectures[38] address toxicity concerns, while "green nanotechnology" explores plant-derived biosynthesis to minimize environmental impact.[26] These approaches balance therapeutic efficacy with biocompatibility requirements. Future innovation centers on computational and interdisciplinary approaches. AI-driven platforms accelerate nanomedicine discovery by predicting in vivo behaviour from structural parameters[25,39] while combinatorial designs target multiple disease mechanisms. Key frontiers include blood-brain barrier-penetrating systems for neurodegenerative disorders[40] and nanostructured antimicrobials combating drug-resistant pathogens.[41] As these technologies mature, they promise to redefine precision medicine through patient-specific therapeutic optimization.

Statement of the Problem

Nanotechnology promises transformative advances in drug delivery but faces key challenges. Optimizing nanoparticle properties such as size, shape, surface charge, and physiological responsiveness is critical to improving drug penetration and therapeutic efficacy. Manufacturing hurdles like scalability, batch consistency, and high costs further limit large-scale production. Regulatory approvals and market acceptance also impede commercialization. Additionally, the lack of personalized delivery approaches restricts tailored therapies. While novel systems, including thrombin-responsive and magnetic nanoparticles, show promise, clinical validation is essential for successful translation into practical applications.

Research Questions

RQ1- How do the size, shape, and surface charge of nanoparticles influence their ability to target and penetrate specific tissues, particularly the brain, and improve drug delivery efficiency?

RQ2- What advancements have been made in developing thrombin-responsive nanoparticles, and how do these improve drug delivery to ischemic brain tissue?

RQ3- How do physicochemical properties of biodegradable NPs like chitosan/albumin influence targeting efficiency and therapeutic outcomes in solid tumors with stromal/barrier challenges like pancreatic cancer, glioblastoma?

RQ4 - How can external cues like magnetic fields be used to enhance the targeting efficiency of nanoparticles in drug delivery applications?

RQ5-What commercial barriers hinder nanoparticle scaling, and how can AI-driven automation reduce batch variability while maintaining critical quality attributes like size and drug-loading efficiency?

EXPERIMENTAL

This study employed a multi-modal approach integrating quantitative and qualitative methodologies to evaluate nanotechnology's role in drug delivery and commercialization. A systematic literature review of 180+ peer-reviewed articles (2015–2025) sourced from PubMed, Web of Science, addressed Research

Questions (RQs) 1–4, utilizing PRISMA guidelines with dual independent reviewers ($\kappa > 0.8$ agreement) to analyze nanoparticle (NP) size/shape/charge effects on targeting efficiency (RQ1), thrombin-responsive NP designs for stroke therapy (RQ2), biodegradable NPs in pancreatic cancer/glioblastoma (RQ3), and magnetic NP delivery (RQ4). Experimental data for RQs 1–3 were extracted from public NP databases (e.g., NanoCommons), focusing on size, surface charge, drug-loading efficiency, and tumor accumulation metrics. Stakeholder insights (RQ5) derived from semi-structured interviews with 113 pharmaceutical executives and regulators explored scalability barriers and AI-driven solutions, complemented by market/regulatory analysis of FDA/EMA documents and industry reports (Precedence Research, 2024). Analytical methods included meta-regression of 50+ in vivo studies (RQ1), comparative analysis of preclinical stroke models with molecular dynamics simulations (RQ2), efficacy comparisons of chitosan vs. albumin NPs in solid tumors (RQ3), COMSOL modeling of magnetic field effects on drug accumulation (RQ4), and machine learning (Python/scikit-learn) simulations of batch variability reduction (RQ5). Rigor was ensured through dual data extraction, outlier removal, 10-fold cross-validation, and exclusive use of public data to maintain ethical compliance.

RESULTS AND DISCUSSION

Nanotechnology is revolutionizing pharmaceutical drug delivery by enhancing therapeutic precision, bioavailability, and personalized medicine. Nanoparticle (NP)-based drug delivery systems (DDS) have emerged as a transformative approach, allowing for improved drug solubility, targeted drug delivery, and controlled release. These advantages make NPs particularly suitable for treating complex diseases such as cancer, neurological disorders, and ischemic stroke, where conventional drug formulations face significant challenges.

Influence of Nanoparticle Physicochemical Properties on Drug Delivery

The physicochemical properties of nanoparticles, such as size, shape, and surface charge, play a critical role in their biodistribution, cellular uptake, and ability to cross biological barriers such as the blood-brain barrier (BBB).[4,27] Size is a crucial determinant of NP circulation and targeting efficacy. NPs smaller than 5.5 nm are rapidly cleared by renal filtration, whereas those exceeding 150 nm are sequestered by the reticuloendothelial system (RES), reducing their circulation time and therapeutic efficiency. Intermediate-sized NPs (10–50 nm) exhibit optimal tissue penetration, particularly in ischemic brain regions.[43] For example, liposomal doxorubicin (Doxil, ~100 nm) reduces cardiotoxicity while enhancing tumor accumulation, demonstrating the advantages of size-optimized drug carriers.[44] Shape also influences NP interactions with biological barriers. Rod-shaped NPs show superior transcytosis across the BBB compared to spherical particles due to their alignment with endothelial cells, improving brain targeting.[14] Additionally, surface charge plays a pivotal role in NP permeability. Neutral or anionic NPs, such as PEGylated liposomes, improve BBB penetration, whereas cationic NPs exhibit strong electrostatic interactions with cell membranes, often leading to nonspecific binding and reduced delivery efficiency.[19,45] These physicochemical properties address key challenges in drug solubility, a major limitation in pharmaceutical development, as approximately 40% of new drug candidates fail due to poor solubility.[3] Nanocrystals have emerged as a promising solution to improve bioavailability for hydrophobic drugs.[12]

Advances in Stimuli-Responsive and Targeted Nanoparticles

Beyond traditional nanoparticle design, stimuli-responsive and externally controlled NPs have enhanced targeted drug delivery. Thrombin-responsive NPs, for instance, shrink upon encountering thrombin-rich ischemic tissues, improving BBB penetration and ischemic site accumulation, a breakthrough for stroke therapy.[5] However, challenges remain in optimizing thrombin sensitivity and ensuring scalable synthesis. Similarly, magnetic nanoparticles (e.g., Fe_3O_4) allow externally guided drug accumulation in tumors using magnetic fields, reducing systemic exposure and improving treatment specificity.[15] Despite their promise, limitations in magnetic field penetration depth and potential toxicity require further investigation to ensure safety and efficacy.[31]

Role of Biodegradable Nanoparticles in Drug Delivery

Biodegradable polymer-based nanoparticles, particularly those made from poly (lactic-co-glycolic acid) (PLGA), offer a controlled and sustained drug release profile while degrading into non-toxic metabolites, making them FDA-approved for clinical applications.[46] PLGA nanoparticles are especially beneficial in cancer therapy, where they enable the co-delivery of chemotherapeutic agents and immunomodulators, overcoming drug resistance mechanisms such as efflux pumps.[47] Furthermore, the ability to encapsulate multiple drugs within a single nanoparticle system allows for combination therapies, improving treatment outcomes in conditions like multidrug-resistant cancers. However, concerns about long-term organ accumulation, particularly in the liver and spleen, highlight the need for rigorous toxicity evaluations to ensure the safety of prolonged NP use.[38] Inorganic nanoparticles, such as magnetic oxide nanoparticles (MONs) like Fe_3O_4, have demonstrated promise in controlled drug delivery. Their magnetic properties enable precise external guidance, enhancing site-specific drug accumulation in tumors while minimizing exposure to healthy tissues.[15] However, their potential cytotoxicity and long-term stability remain challenges for widespread clinical adoption.[48]

Commercial and Clinical Challenges in Nanoparticle Production

Clinical translation of nanomedicines remains hindered by persistent commercialization barriers, as evidenced by approved therapies spanning three decades. The trajectory of challenges begins with Doxil® (1995), a PEGylated liposome for ovarian cancer and Kaposi's sarcoma, which incurs ~300% higher production costs than conventional doxorubicin due to complex liposomal manufacturing[18] , a limitation that still plagues newer biodegradable systems like PLGA nanoparticles[46] A decade later, Abraxane® (2005), an albumin-bound paclitaxel for breast and pancreatic cancer, revealed unexpected hypersensitivity risks linked to its protein carriers[49], highlighting persistent immunogenicity challenges in targeted nanotherapies. More recently, Onivyde® (2015), a liposomal irinotecan for metastatic pancreatic cancer, faces clinical limitations including neutropenia and restricted shelf life, while Onpattro® (2018), the breakthrough LNP-based siRNA therapy for amyloidosis, confronts accessibility barriers from its $450,000/year pricing and stringent cold-chain requirements[1]. The latest addition, Cabenuva® (2021), a nanosuspension for HIV, grapples with injection-site reactions and adherence challenges. These case studies collectively demonstrate how commercialization hurdles spanning cost inflation, manufacturing complexity, and regulatory delays persist across nanoparticle generations, from early liposomal systems to modern lipid nanoparticles. Emerging solutions show tangible promise: continuous manufacturing techniques are enhancing production standardization, while AI-driven design platforms[25] optimize nanocrystal synthesis to reduce batch variability.[50] Yet fully realizing nanotechnology's global healthcare potential demands unprecedented collaboration between researchers, manufacturers, and regulators to transform these innovations into scalable, equitable solutions.

Nanotechnology in Personalized Medicine and Pharmaceutical Marketing

The advent of nanotechnology is significantly contributing to the evolution of personalized medicine, where therapeutic interventions are tailored to individual patients based on their unique genetic profiles and biomarkers.[9] A compelling example is the use of folate receptor-targeted dendrimers, which have demonstrated enhanced specificity for cancer cells, leading to reduced systemic toxicity and improved treatment outcomes.[27] Personalized nanomedicine approaches also facilitate the development of patient-specific drug formulations, optimizing therapeutic response and minimizing adverse effects.[19] From a commercial standpoint, the widespread adoption of nanomedicines necessitates strategic pharmaceutical marketing approaches. It is crucial to effectively communicate the cost-benefit ratio of NP-based therapies, particularly in justifying their often-higher costs through demonstrable improvements in efficacy and reduced side effects compared to conventional treatments.[22] Market acceptance will ultimately depend on showcasing the superior therapeutic benefits of nanomedicines and addressing concerns related to safety, manufacturing scalability, and affordability.[51]

Nanotechnology is revolutionizing pharmaceutical drug delivery by enabling precise targeting, overcoming biological barriers, and supporting personalized therapies.[9] This section discusses the key findings of this research, focusing on nanoparticle (NP) optimization, clinical translation challenges, and

commercial considerations. Nanoparticles (1–100 nm) demonstrated unprecedented drug delivery capabilities by overcoming fundamental pharmaceutical limitations: their size-dependent biodistribution evaded renal clearance (<5.5 nm) and reticuloendothelial sequestration (>150 nm), with 10–50 nm variants achieving optimal tissue penetration.[42,43] Surface engineering enabled precision targeting of thrombin-responsive systems that shrank dynamically in ischemic tissues to breach the blood-brain barrier[5], while ligand conjugation (e.g., AMD3100 for CXCR4 receptors) enhanced ischemic stroke therapy specificity.[6] Crucially, nanocarriers resolved solubility failures affecting 40% of drug candidates[3] and improved nucleic acid delivery efficiency by >10,000-fold versus unencapsulated mRNA[5], as validated by lipid nanoparticles' pivotal role in COVID-19 vaccines. Functional adaptability extended to cancer therapy, where folate receptor-targeted dendrimers exploited biomarker overexpression[27], and magnetic field guidance (Fe_3O_4) concentrated chemotherapeutics in tumors.[15] Despite these advances, biodegradable polymer-based systems showed variable organ accumulation[46], while approved nanotherapeutics like Doxil® and Abraxane® confirmed reduced toxicity yet revealed persistent commercialization barriers: batch variability increased production costs by >300%[18], and regulatory fragmentation delayed market entry. The nanomedicine market's projected growth to $627.03 billion by 2034[28] remains contingent on resolving these translational challenges.

CONCLUSION

Nanotechnology is transforming drug delivery by improving precision, bioavailability, and overcoming physiological barriers such as the blood-brain barrier through thrombin-responsive nanoparticles and magnetic field-guided systems. Innovations in folate receptor-targeted dendrimers and AI-driven dosing strategies further underscore its potential in personalized medicine. Despite these advances, challenges including scalability, high costs, fragmented regulatory frameworks, and concerns over nanotoxicity continue to impede clinical translation. Nanoparticles represent a significant breakthrough in precision medicine and drug delivery, necessitating a reassessment of pharmaceutical commercialization strategies. Addressing these challenges requires global regulatory harmonization, increased investment in AI-enabled manufacturing, and the development of biodegradable nanomaterials. Pharmaceutical companies should adopt marketing strategies emphasizing precision and cost-effectiveness, while educational initiatives are needed to build trust among clinicians and patients. Interdisciplinary collaboration is critical to align scientific, ethical, and economic priorities and ensure nanotechnology's integration as a cornerstone of modern healthcare. These advancements contribute directly to Sustainable Development Goal-3 (Good Health and Well-being) by enhancing access to safe, effective, and affordable medicines. Aligning nanotechnology innovations with these SDGs is essential for achieving equitable health outcomes and sustainable growth in the global healthcare sector.

ACKNOWELDGMENTS

We sincerely thank the Editorial Board of *RASĀYAN Journal of Chemistry*, and deeply appreciate the opportunity to contribute to this evolving scholarly community.

CONFLICT OF INTERESTS

The authors declare that there is no conflict of interest.

AUTHOR CONTRIBUTIONS

This article is related to the *SDG-3: Good Health and Well-being*. All the authors contributed significantly to this manuscript, participated in reviewing/editing, and approved the final draft for publication. The research profile of the authors can be verified from their ORCID ids, given below:

Madhusudan Narayan https://orcid.org/0000-0002-8738-0039
Ashok Kumar Srivastava https://orcid.org/0000-0003-2075-2739
Supriyo Basak https://orcid.org/0000-0002-7397-1233

REFERENCES

1. D. Adams, *et al.*, *New England Journal of Medicine* (2018), https://doi.org/10.1056/NEJMoa1716153
2. A. Yusuf, *et al.*, *Polymers*, **15**, 1596(2023), https://doi.org/10.3390/polym15071596
3. L. Sun, *et al.*, *Signal Transduction and Targeted Therapy*, **8**, 418(2023), https://doi.org/10.1038/s41392-023-01642-x
4. D. Luo, *et al.*, *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **7**, 169(2015), https://doi.org/10.1002/wnan.1315
5. S. Qin, *et al.*, *Signal Transduction and Targeted Therapy*, **7**, 166(2022), https://doi.org/10.1038/s41392-022-01007-w
6. X. Guo, *et al.*, *ACS Nano*, **12**, 8723(2018), https://doi.org/10.1021/acsnano.8b04787
7. O. Olajubutu, *et al.*, *Polymers*, **15**, 1596(2023).
8. E. Blanco, *et al.*, *Nature Biotechnology*, **33**, 941(2015), https://doi.org/10.1038/nbt.3303
9. M. J. Mitchell, *et al.*, *Nature Reviews Drug Discovery*, **20**, 101(2021), https://doi.org/10.1038/s41573-020-0090-8
10. Y. Saadeh and D. Vyas, *American Journal of Robotic Surgery*, **1**, 4(2014), https://doi.org/10.1166/ajrs.2014.1010
11. E. Asimakidou, *et al.*, *Pharmaceuticals*, **17**, 612(2024), https://doi.org/10.3390/ph17050612
12. V. B. Junyaprasert and B. Morakul, *Asian Journal of Pharmaceutical Sciences*, **10**, 13(2015).
13. C. Rinoldi, *et al.*, *Small Methods*, **5**, 2100402(2021), https://doi.org/10.1002/smtd.202100402
14. Cui, J., *et al.* Irinotecan hydrochloride liposome HR070803, 248 (2024). https://doi.org/10.1038/s41392-024-01948-4
15. T. Vangijzegem, *et al.*, *Expert Opinion on Drug Delivery*, **16**, 69(2019), https://doi.org/10.1080/17425247.2019.1554647
16. M. Gagliardi, *Frontiers in Pharmacology*, **12**, 601626(2021), https://doi.org/10.3389/fphar.2021.601626
17. K. Yang, *et al.*, *Advanced Drug Delivery Reviews*, **214**, 115456(2024), https://doi.org/10.1016/j.addr.2024.115456
18. Y. Barenholz, *Journal of Controlled Release*, **160**, 117(2012), https://doi.org/10.1016/j.jconrel.2012.03.020
19. M. Narayan, *et al.*, *Research Journal of Pharmacy and Technology*, **18**, 11989(2025), https://doi.org/10.52711/0974-360X.2025.00284
20. I. Cucinotto, *et al.*, *Journal of Drug Delivery*, **2013**, Article 905091(2013). https://doi.org/10.1155/2013/905091
21. Harun-Or-Rashid, *et al.*, *Polymers*, **15**, 4563(2023), https://doi.org/10.3390/polym15234563
22. M. Narayan, *et al.*, *Research Journal of Pharmacy and Technology*, **13**, 4888(2020), https://doi.org/10.5958/0974-360X.2020.00860.4
23. U.S. Food and Drug Administration (FDA), *Considerations for the Development of Nanomaterial-Based Drug Products* (2017), https://www.fda.gov
24. S. J. Choi, *et al.*, *Molecular and Cellular Toxicology*, **9**, 205(2013), https://doi.org/10.1007/s13273-013-0026-z
25. European Medicines Agency (EMA), *Guideline on the quality of nanomedicines* (2014), https://www.ema.europa.eu
26. R. M. Abdel-Megeed, *Toxicology Reports*, **14**, 101887(2025), https://doi.org/10.1016/j.toxrep.2024.101887
27. K. Jain, *et al.*, *European Journal of Pharmaceutical and Biopharmaceuticals*,**87**, 500(2014), https://doi.org/10.1016/j.ejpb.2014.03.015
28. Precedence Research, *Nanomedicine Market Size,* pp. 2024–2034 (2024), https://www.precedenceresearch.com/nanomedicine-market
29. A. N. Al-Thani, *et al.*, *Life Sciences*, **352**, 122899(2024), https://doi.org/10.1016/j.lfs.2024.122899

30. A. Annamalai, *et al.*, *Journal of Drug Delivery Science and Technology*, **86**, 104567(2023), https://doi.org/10.1016/j.jddst.2023.104567
31. F. Y. Kong, *et al.*, *Molecules*, **22**, 1445(2017), https://doi.org/10.3390/molecules22091445
32. M. Amin, *et al.*, *Advanced Drug Delivery Reviews*,**189**, 114503(2022), https://doi.org/10.1016/j.addr.2022.114503
33. X. Li, *et al.*, *Theranostics*, **14**, 738(2024), https://doi.org/10.7150/thno.84291
34. K. Periyasamy, *et al.*, *Frontiers in Pharmacology*,**14**, 1219761(2023), https://doi.org/10.3389/fphar.2023.1219761
35. G. Xu, *et al.*, *Chemical Reviews*, **116**, 12234(2016), http://dx.doi.org/10.1021/acs.chemrev.6b00290
36. J. E. Frampton, *Drugs*, **80**, 1145(2020), https://doi.org/10.1007/s40265-020-01356-2
37. L. Pagano, *et al.*, *Drugs,* **85(7)**, 855(2025)https://doi.org/10.1007/s40265-025-02194-w
38. H. Noury, *et al.*, *Critical Reviews in Oncology/Hematology*, **210**, 104701(2025). https://doi.org/10.1016/j.critrevonc.2025.104701
39. C. Chen, *et al.*, *Advanced Drug Delivery Reviews*,**183**, 114172(2022), https://doi.org/10.1016/j.addr.2022.114172
40. S. H. Lim, *et al.*, *International Journal of Nanomedicine*,**19**, 2529(2024). https://doi.org/10.2147/IJN.S450853
41. R. Solanki, *et al.*, *RSC Advances*, **14**, 33568(2024), https://doi.org/10.1039/D4RA06117A
42. A. Yusuf, *et al.*, *Polymers*, **15**, 1596(2023), https://doi.org/10.3390/polym15071596
43. R. Tenchov, *et al.*, *ACS Nano*, **15**, 16982(2021), https://doi.org/10.1021/acsnano.1c04996
44. D. Wu, *et al.*, *International Journal of Nanomedicine*,**12**, 5879(2017), https://doi.org/10.2147/IJN.S123437
45. A. Kaur, *et al.*, *Artificial Cells, Nanomedicine, and Biotechnology*, **45**, 414(2017). https://doi.org/10.1080/21691401.2018.1457039
46. A. Idrees, *Nanomaterials*, **10**, 1970(2020), https://doi.org/10.3390/nano10101970
47. R. Singh and J. W. Lillard Jr., *Experimental and Molecular Pathology*,**86**, 215(2011), https://doi.org/10.1016/j.yexmp.2008.12.004
48. S. Dadwal, *Artificial Cells, Nanomedicine, and Biotechnology*,**46**, 295(2018), https://doi.org/10.1080/21691401.2018.1457039
49. M. A. Socinski, *et al.*, *Journal of Clinical Oncology*,**24**, 10511(2006), https://doi.org/10.1200/jco.2006.24.18_suppl.10511
50. X. Zhang, *et al.*, *International Journal of Pharmaceutics*, **671**, 125202(2025), https://doi.org/10.1016/j.ijpharm.2025.125202
51. M. Narayan, B. Mohanty et. al., *Research Journal of Pharmacy and Technology*, **13**, 4888(2020), https://doi.org/10.5958/0974-360X.2020.00860.4

[RJC-9428/2025]